Jubilant Ingrev. Q1 FY27 Earnings Call — Analysis (NSE: JUBLINGREA)

Jubilant Ingrevia reports strong Q1FY27 with revenue hitting a 15-quarter high of ₹1,300 Cr, EBITDA up 36% YoY, and maintains FY27 guidance of ₹750–800 Cr despite CDMO contract pause.

27 Jul 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Consolidated Revenue ₹1,300 Cr ( +25% YoY ) . New guidance — FY27 fy27 consolidated ebitda ₹750–800 Cr . New story: CDMO pipeline momentum and diversification .

Results

Revenue ₹1,300 Cr +25% YoY; EBITDA ₹209 Cr +36% YoY (+22% QoQ); PAT ₹106 Cr +41% YoY; Specialty Chemicals revenue ₹533 Cr +11% YoY, EBITDA margin 26%; Nutrition revenue ₹243 Cr +36% YoY, EBITDA ₹36 Cr +45% YoY; Chemical Intermediates revenue ₹524 Cr +38% YoY, EBITDA ₹57 Cr +240% YoY.

Financial highlights

Guidance

FY27 EBITDA guidance maintained at ₹750–800 Cr; H1FY27 EBITDA expected ~₹400 Cr+; sequential revenue and EBITDA growth projected for remaining quarters; growth driven by Specialty Chemicals, Nutrition and acetyls recovery.

What management committed to

• FY27 EBITDA will be in the range of ₹750–800 Cr. — ₹750–800 Cr, FY27
• H1 FY27 EBITDA will be around ₹400 Cr+. — ₹400 Cr+, H1FY27
• Revenue and EBITDA will improve sequentially over the coming quarters of FY27. — Q2FY27-Q4FY27
• Specialty Chemicals and Nutrition will lead FY27 growth alongside recovery in acetyls. — FY27
• Specialty and Nutrition will account for 70-80% of total EBITDA in FY27. — 70-80%, FY27
• The new niacinamide plant utilization will reach 70%+ of peak volumes by end of calendar year 2026. — 70%+, Q3FY27
• The new multipurpose plant (MPP) will be commissioned by end of current calendar year. — Q3FY27
• We will achieve INR100 Cr of lean savings in FY27. — ₹100 Cr, FY27
• Even if the large CDMO contract customer gives no further volumes in FY27, contractual protection will ensure the EBITDA expectations from the contract are met. — FY27

Key themes

CDMO pipeline acceleration and specialty mix shift

How the narrative shifted

• CDMO pipeline momentum and diversification: Management positions the growing CDMO funnel (>100 molecules, ₹3,500 Cr potential) as the primary structural growth engine, with near-term commercial traction from the large agro contract and a broadening pipeline across pharma, semicon and personal care.
• Agro CDMO contract uncertainty hedged: Volumes were paused by the innovator due to raw material cost spikes, but management repeatedly assures full contractual protection on EBITDA; revenue trajectory unclear, but embedded downside protection maintains conviction.
• Specialty mix shift toward high-margin segments: Growth increasingly driven by CDMO, fine chemicals and nutrition, while mature pyridine sees pricing pressure; specialty and nutrition expected to deliver 70-80% of EBITDA, improving overall margin profile.
• Acetyls recovery but structurally volatile: Chemical Intermediates posted a sharp rebound due to robust demand and cost pass-through, and Q2 is holding up; however, management refuses to extrapolate into H2 given geopolitics and oil price volatility.
• Capacity expansion on track: New MPP plant commissioning by end-2026 and niacinamide plant ramp to 70%+ utilisation provide near-term capacity headroom; these assets are positioned to capture CDMO and nutrition demand.
• Geopolitical and raw material volatility: Middle East disruption and oil price movements impacted raw material and logistics costs, but the company frames its diversified sourcing and cost pass-through capability as a mitigant.

Operational commentary

• CDMO business momentum: large agro innovator contract started supplies in March; Q1 volumes temporarily paused by customer due to raw material price escalation but EBITDA protection covers expectations; higher volumes expected in Q2.
• CDMO pipeline expanded: funnel over 100 molecules with ₹3,500+ Cr peak revenue potential; 25+ confirmed molecules (added 5 this quarter across pharma, semicon, personal care); advanced-stage pipeline remains at ~10 molecules with dynamic composition.
• Niacinamide new plant (5,000-ton capacity) utilisation reached 50% of peak volumes; management targets 70%+ utilisation by end of calendar year 2026.
• New multipurpose plant (MPP) on track for commissioning by end of calendar year 2026, strengthening CDMO and fine chemicals growth.
• Personal Care: over 20 products under development, increasing traction; semiconductors/electronics: dedicated R&D and clean room facility being built at Greater Noida.
• Nutrition segment: Human Nutrition benefited from strong niacinamide pricing and volume growth; Animal Nutrition Vitamin B3 pricing significantly improved; choline demand healthy from Europe.
• Chemical Intermediates (acetyls) rebounded sharply on robust demand and cost pass-through; management sees continued strength in Q2 but remains cautious on sustainability through Q3/Q4 due to volatility.
• Remidex Pharma integration completed; encouraging traction with Tier 1 human nutrition customers in premixes.
• Lean savings target of ₹100 Cr for FY27; progressing well.

Analyst Q&A

• Q. Can you quantify the contribution of the large CDMO contract in Q1 and the full-year EBITDA expectation if volumes remain lower?

  Volumes were temporarily paused by the innovator due to raw material price escalation; the plant ran smoothly and generated positive EBITDA; we maintain our earlier EBITDA expectations for this contract; we have full contractual protection that will more than cover the EBITDA expectation even if no further volumes materialise.

• Q. Any possibility of upgrading the full-year guidance of ₹750–800 Cr EBITDA given the strong start?

  Guidance maintained at ₹750–800 Cr; H1 EBITDA around ₹400 Cr+; sequential improvement expected; optimism exists if acetyls hold up, but Q3/Q4 volatility risk prevents an upgrade at this stage.

• Q. What is the break-up of the confirmed CDMO order book by end-use industry?

  Approximately 20-25% agro, 30% pharma, 10-15% industrial, 15% nutrition, 10% consumer; the broader pipeline mirrors this mix.

• Q. Why was sequential revenue growth in Specialty Chemicals only ₹17 crore despite the CDMO contract ramp?

  Q4 is a seasonally heavy quarter due to year-end customer buying; additionally, some CDMO volumes were pushed to Q2 due to raw material price spikes; pyridine pricing pressure offset some growth; year-on-year comparison (+11%) more accurately reflects the momentum.

• Q. Will the large CDMO contract customer provide a timeline for full volume visibility?

  No firm timeline yet; need clarity by next month to plan for Q3; hopeful for more visibility then.

View source

Research and educational content only. Not investment advice.